Founded: 2009
Headquarters: Redwood City, California
Already have an account? Sign In
PROCEPT BioRobotics, founded in 2009 and headquartered in Redwood City, California, is a surgical robotics company specializing in urology. Their flagship product is an innovative surgical robotic system that uses image-guided, heat-free therapy to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. This advanced system combines real-time multidimensional imaging, personalized treatment planning, automated robotics, and waterjet ablation technology for precise and efficient prostate tissue removal.
The company has successfully raised a total of $348.84 million in funding, demonstrating significant investor interest in their cutting-edge medical technology. PROCEPT BioRobotics' focus on addressing a common urological condition with a novel approach positions them as a potential disruptor in the healthcare sector.
As of now, there is no concrete information available regarding PROCEPT BioRobotics' IPO prospects. The company has not made any official announcements about plans to go public, and we have not found any credible reports or rumors suggesting an imminent IPO. Investors interested in PROCEPT BioRobotics should keep an eye on official company communications and reputable financial news sources for any updates on potential IPO plans.
It's important to note that various factors can influence a company's decision to go public, including market conditions, financial performance, and strategic goals. For PROCEPT BioRobotics, considerations such as the growth of the surgical robotics market, advancements in urological treatments, and the company's own financial health and market position could play a role in any future IPO decisions.
Already have an account? Sign In
While PROCEPT BioRobotics' IPO prospects remain uncertain, investors eager to explore opportunities in the innovative medical technology space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the healthcare and robotics sectors, like PROCEPT BioRobotics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of cutting-edge medical technology firms before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.